Liquiritigenin
英文名称: Liquiritigenin
型号:null    产品货号: IHR1041-0010MG
价格:请致电:010-57128832,18610462672
品牌: gene operation

 IHR1041 Liquiritigenin中文网页版)

Liquiritigenin>98%

【英文同义名】:4,7-Dihydroxyflavanone; 7,4-Dihydroxyflavanone; ()-liquiritigenin

【中文同义名】:甘草素

订购信息:(原装进口,常备现货)

 

产品名称

产品货号

目录价(元)

Gene Operation

Liquiritigenin

IHR1041-0010MG

10 mg

¥2,829.00

IHR1041-0020MG

20 mg

¥4,529.00

产品描述

Liquiritigenin是一种在许多植物(如甘草)中发现的雌***化合物,具有高度选择性的ERβ (雌***受体β)激动剂, 其激活ERE tk-LucEC50=36.5nM, 呈现20倍的ERβ高度选择性,而对其他核受体,如雄***、糖皮质***受体等均无激活作用[1]Liquiritigenin具有抗炎性,能够抑制巨噬细胞中NF-κB活化,并降低LPS诱导的iNOS 和促炎症细胞因子产物,如TNF-αIL-1βIL-6。在大鼠中,liquiritigenin还可以抑制卡拉胶(carrageenan)诱导的足肿胀[2]Liquiritigenin还具有细胞保护作用,在培养的肝细胞中能抑制重金属诱导的毒性反应,并保护大鼠免受对乙酰氨基酚(acetaminophen)和丁硫氨酸亚砜胺(buthione sulfoximine (BSO))诱导的肝损伤。另外,liquiritigenin具有促胆汁分泌作用,以及诱导肝脏中转运蛋白和phase-II酶的表达[3]

靶点

 

靶点

Estrogen receptor β

EC50(半数有效浓度)

36.5 nM

化学特性

CAS No.: 578-86-9

M. Wt.: 256.25

Formula: C15H12O4

Purity: >98 %

Synonym: 4,7-Dihydroxyflavanone; 7,4-Dihydroxyflavanone; (−)-liquiritigenin

Chemical Name:  (S)-2,3-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one

Appearance: Off-white solid to Yellow solid

Solubility: Soluble to 100 mM in DMSO and to 100 mM in ethanol

StorageStore at -20 ºC

储存液配制

储存液 (1 ml DMSO体系)

10mM

20mM

30mM

质量(mg)

2.5625

5.1250

7.6875

结构式

使用浓度(仅作参考)

Liquiritigenin具体使用浓度请参考相关文献,并根据自身实验条件(如实验目的,细胞种类,培养特性等)进行摸索和优化。

参考文献

[1] Mersereau, J.E., et al. Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist. Molecular and Cellular Endocrinology 283(1-2): 49–57(2008).

[2] Kim, Y.W., et al. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NK-kappaB-dependent iNOS and proinflammatory cytokines production. Br. J. Pharmacol.154: 165-173(2008).

[3] Kim, Y.W., et al. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. American journal of physiology. Gastrointestinal and liver physiology 296 (2): G372–81(2009).